• PA
    PA School SurvivalDidactic Year
Study
  • Dashboard
  • Medical Terminology
  • Flashcards
  • Progress
  • Prep Rounds
  • Body Systems
  • Pharmacology
  • Tools
  • Guide & FAQ
  • Suggest a FeatureLet us know what we can do better — we genuinely want to help you in class.
My material
  • My Library
  • Notes & Sketches
PANCE Body Systems
  • Cardiovascular
    11%
  • Pulmonary
    9%
  • Gastrointestinal/Nutrition
    8%
  • Musculoskeletal
    8%
  • Neurology
    7%
  • Infectious Disease
    7%
  • Psychiatry/Behavioral
    7%
  • Reproductive
    7%
  • Endocrine
    6%
  • Eyes/Ears/Nose/Throat
    6%
  • Hematology
    5%
  • Renal
    5%
  • Genitourinary
    4%
  • Dermatology
    4%
Weights are study aids — verify each exam cycle.
⌘K
NotesPricingSign in
About·Tools·Terminology·Privacy Policy·Terms of Service·PANCE Blueprint

PANCE® is a registered trademark of the National Commission on Certification of Physician Assistants (NCCPA). This application is an independent study resource and is not affiliated with, sponsored by, or endorsed by the NCCPA.

For educational use only. Content is AI-generated, may contain errors, and is not medical advice — always verify against current primary sources and faculty guidance before clinical use.

HomePulmonaryAsthma

Asthma

Pulmonary · ~9% of blueprint
Pathophysiology
Airway inflammation + bronchial hyperresponsiveness → reversible bronchoconstriction, mucus, and edema.
Signs & Symptoms
Episodic wheeze, cough, chest tightness, dyspnea; worse at night/with triggers; prolonged expiration.
Gold Standard Diagnosis
Spirometry: obstructive pattern (↓ FEV1/FVC) with ≥12% reversibility after a bronchodilator.
First-line Treatment
Inhaled corticosteroid (ICS) is the controller foundation; current guidelines favor as-needed ICS-formoterol (SMART) as the preferred reliever over a SABA alone. Step up controller therapy (add LABA) by symptom control.
Drug cardsFluticasoneAlbuterolSalmeterolMontelukast
High-Yield Pearl

Reversibility on spirometry separates asthma from COPD. Every asthmatic needs ICS-containing therapy — guidelines now favor ICS-formoterol as reliever, not SABA monotherapy.

More Pulmonary conditions

  • COPD
  • Pulmonary Embolism
All Pulmonary